ID Biochemical seeks to market infection test:
This article was originally published in Clinica
Executive Summary
ID Biochemical has filed for US FDA 510(k) clearance to market its rapid gene test for methicillin-resistant Staphylococcus aureus (MRSA), the cause of potentially fatal infection which is prevalent in hospitals. Data from clinical trials at four US hospitals showed that the Velogene Rapid MRSA test correctly identified 99.3% of samples when compared with conventional susceptibility tests and 100% when compared with results from the "gold standard" gene identification technology, PCR. Based on the Vancouver, British Columbia company's Cycling Probe Technology, the new test detects the MecA gene responsible for methicillin resistance.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.